|
Johnson, S W; Laub, P B; Beesley, J S et al. (1997) Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res 57:850-6
|
|
O'Dwyer, P J; Hamilton, T C; LaCreta, F P et al. (1996) Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol 14:249-56
|
|
Johnson, S W; Lissy, N A; Miller, P D et al. (1996) Identification of zinc finger mRNAs using domain-specific differential display. Anal Biochem 236:348-52
|
|
Yao, K S; Godwin, A K; Johnson, S W et al. (1995) Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. Cancer Res 55:4367-74
|
|
O'Dwyer, P J; Hamilton, T C; Yao, K S et al. (1995) Modulation of glutathione and related enzymes in reversal of resistance to anticancer drugs. Hematol Oncol Clin North Am 9:383-96
|
|
Lacreta, F P; Brennan, J M; Hamilton, T C et al. (1994) Stereoselective pharmacokinetics of L-buthionine SR-sulfoximine in patients with cancer. Drug Metab Dispos 22:835-42
|
|
Hamaguchi, K; Godwin, A K; Yakushiji, M et al. (1993) Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res 53:5225-32
|
|
Johnson, S W; Ozols, R F; Hamilton, T C (1993) Mechanisms of drug resistance in ovarian cancer. Cancer 71:644-9
|
|
Yao, K; Godwin, A K; Ozols, R F et al. (1993) Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment. Cancer Res 53:3662-6
|
|
Hamilton, T C; O'Dwyer, P J; Ozols, R F (1993) Platinum analogues in preclinical and clinical development. Curr Opin Oncol 5:1010-6
|
Showing the most recent 10 out of 14 publications
